Organovo Holdings, Inc. (0R02.L)
USD 0.38
(-3.43%)
USD 0.38
(-3.43%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -15.08 Million USD | 14.92% |
| 2022 | -17.73 Million USD | -54.46% |
| 2021 | -11.47 Million USD | 31.78% |
| 2020 | -16.82 Million USD | 21.65% |
| 2019 | -21.47 Million USD | 21.26% |
| 2018 | -27.27 Million USD | 22.67% |
| 2017 | -35.27 Million USD | 8.57% |
| 2016 | -38.57 Million USD | 0.18% |
| 2015 | -38.64 Million USD | -27.55% |
| 2014 | -30.29 Million USD | -46.72% |
| 2013 | -20.64 Million USD | -121.58% |
| 2012 | -9.31 Million USD | 0.0% |
| 2010 | -147.81 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -3.38 Million USD | -9.37% |
| 2023 Q3 | -3.68 Million USD | 10.57% |
| 2023 Q1 | -4.19 Million USD | 46.07% |
| 2023 Q2 | -4.11 Million USD | 1.91% |
| 2023 FY | -15.08 Million USD | 14.92% |
| 2023 Q4 | -3.09 Million USD | 15.87% |
| 2022 FY | -17.73 Million USD | -54.46% |
| 2022 Q4 | -7.77 Million USD | -131.59% |
| 2022 Q3 | -3.35 Million USD | -0.15% |
| 2022 Q2 | -3.35 Million USD | -3.55% |
| 2022 Q1 | -3.23 Million USD | -69.32% |
| 2021 Q1 | -2.55 Million USD | 1.5% |
| 2021 Q2 | -3.5 Million USD | -37.05% |
| 2021 FY | -11.47 Million USD | 31.78% |
| 2021 Q4 | -1.91 Million USD | 45.34% |
| 2021 Q3 | -3.5 Million USD | 0.2% |
| 2020 Q1 | -2.78 Million USD | 3.7% |
| 2020 Q4 | -2.59 Million USD | -4.25% |
| 2020 Q2 | -8.95 Million USD | -221.25% |
| 2020 FY | -16.82 Million USD | 21.65% |
| 2020 Q3 | -2.49 Million USD | 72.16% |
| 2019 Q2 | -6.82 Million USD | -4.69% |
| 2019 FY | -21.47 Million USD | 21.26% |
| 2019 Q4 | -2.89 Million USD | 44.73% |
| 2019 Q3 | -5.23 Million USD | 23.33% |
| 2019 Q1 | -6.52 Million USD | 8.95% |
| 2018 Q1 | -7.57 Million USD | 0.08% |
| 2018 FY | -27.27 Million USD | 22.67% |
| 2018 Q4 | -7.16 Million USD | -9.75% |
| 2018 Q3 | -6.52 Million USD | -8.6% |
| 2018 Q2 | -6 Million USD | 20.69% |
| 2017 Q2 | -9.57 Million USD | 6.09% |
| 2017 Q1 | -10.2 Million USD | 4.57% |
| 2017 Q4 | -7.58 Million USD | 4.12% |
| 2017 FY | -35.27 Million USD | 8.57% |
| 2017 Q3 | -7.9 Million USD | 17.43% |
| 2016 Q2 | -9.47 Million USD | -8.0% |
| 2016 Q4 | -10.68 Million USD | -10.97% |
| 2016 FY | -38.57 Million USD | 0.18% |
| 2016 Q1 | -8.77 Million USD | -4.09% |
| 2016 Q3 | -9.63 Million USD | -1.6% |
| 2015 FY | -38.64 Million USD | -27.55% |
| 2015 Q4 | -8.43 Million USD | 19.47% |
| 2015 Q3 | -10.47 Million USD | 7.21% |
| 2015 Q2 | -11.28 Million USD | -33.41% |
| 2015 Q1 | -8.45 Million USD | -6.12% |
| 2014 Q1 | -6.41 Million USD | 4.13% |
| 2014 FY | -30.29 Million USD | -46.72% |
| 2014 Q4 | -7.97 Million USD | -14.5% |
| 2014 Q3 | -6.96 Million USD | 22.28% |
| 2014 Q2 | -8.95 Million USD | -39.72% |
| 2013 FY | -20.64 Million USD | -121.58% |
| 2013 Q2 | -5.6 Million USD | -50.03% |
| 2013 Q1 | -3.73 Million USD | 7.23% |
| 2013 Q4 | -6.68 Million USD | -44.53% |
| 2013 Q3 | -4.62 Million USD | 17.42% |
| 2012 Q1 | -35.38 Million USD | 1.69% |
| 2012 Q2 | 38.47 Million USD | 208.74% |
| 2012 Q3 | -9.56 Million USD | -124.86% |
| 2012 Q4 | -4.02 Million USD | 57.92% |
| 2012 FY | -9.31 Million USD | 0.0% |
| 2011 Q2 | -23.44 Thousand USD | 66.23% |
| 2011 Q1 | -69.43 Thousand USD | -204.06% |
| 2011 Q3 | -43.5 Thousand USD | -85.57% |
| 2011 Q4 | -35.99 Million USD | -82631.41% |
| 2010 Q2 | -25.72 Thousand USD | 0.0% |
| 2010 Q3 | -29.82 Thousand USD | -15.96% |
| 2010 Q4 | -22.83 Thousand USD | 23.44% |
| 2010 FY | -147.81 Thousand USD | 0.0% |
| 2009 Q4 | -17.62 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | 65.721% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 92.641% |
| Codexis, Inc. | -68.06 Million USD | 77.837% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 94.071% |